Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Tax Provisions: 2019-2023

Historic Tax Provisions for Denali Therapeutics (DNLI) over the last 2 years, with Dec 2023 value amounting to $30,000.

  • Denali Therapeutics' Tax Provisions rose 600.00% to $30,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $272,000, marking a year-over-year decrease of 8.72%. This contributed to the annual value of $68,000 for FY2024, which is 126.67% up from last year.
  • According to the latest figures from Q4 2023, Denali Therapeutics' Tax Provisions is $30,000, which was up 600.00% from -$6,000 recorded in Q4 2022.
  • Denali Therapeutics' Tax Provisions' 5-year high stood at $823,000 during Q4 2020, with a 5-year trough of -$575,000 in Q4 2021.
  • For the 3-year period, Denali Therapeutics' Tax Provisions averaged around -$183,667, with its median value being -$6,000 (2022).
  • As far as peak fluctuations go, Denali Therapeutics' Tax Provisions surged by 997.33% in 2020, and later tumbled by 169.87% in 2021.
  • Quarterly analysis of 5 years shows Denali Therapeutics' Tax Provisions stood at $75,000 in 2019, then spiked by 997.33% to $823,000 in 2020, then plummeted by 169.87% to -$575,000 in 2021, then spiked by 98.96% to -$6,000 in 2022, then surged by 600.00% to $30,000 in 2023.
  • Its Tax Provisions was $30,000 in Q4 2023, compared to -$6,000 in Q4 2022 and -$575,000 in Q4 2021.